EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.85), $0.08 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $966 thousand versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
• Sysco adds two directors, targets AI-driven cost savings of $100M